FDA WARNING_LETTER - Topco Associates LLC

The FDA issued a Warning Letter to Topco Associates, LLC, concerning their drug product, "TopCare Earache Relief Ear Drops," following a review of its labeling and marketing. The FDA determined the product is misbranded under Sections 502 and 503, and violates Section 301(a) of the FD&C Act. Marketed as an over-the-counter (OTC) drug, it is classified as a prescription drug under Section 503(b)(1) because it treats conditions like ear pain, which require physician diagnosis and treatment and are not recognized OTC indications. Specifically, the product is misbranded under Section 503(b)(4) for failing to bear the "Rx only" symbol. It also lacks adequate directions for use for an OTC product, as defined in 21 C.F.R. § 201.5, violating Section 502(f)(1). Furthermore, its labeling is false or misleading under Section 502(a) by promoting OTC treatment for a condition inappropriate for self-treatment and failing to differentiate serious causes of ear pain. Although homeopathic, the product does not meet OTC marketing conditions under CPG 7132.15. Topco Associates must take prompt corrective action within fifteen working days, including preventing recurrence, or face potential legal actions like seizure and injunction, and impact on federal contracts.